MCK

Over the past six months, McKesson's stock experienced several notable events. In May 2026, MCK lost 26% from its 52-week high, partly due to a revenue miss where the company reported $96.3 billion against analyst estimates of $101.4 billion, causing a 2.47% stock fall on earnings day, with sector-wide selling leading to an additional 7% drop. Despite the revenue miss, McKesson's full-year fiscal 2026 adjusted operating profit grew 15%, and adjusted EPS increased by 18% to $39.11, with the Oncology and Multispecialty segment seeing a 50% jump in operating income. In August 2026, McKesson reported its fiscal 2027 first-quarter results, raising its full-year adjusted EPS guidance, with quarterly EPS of $9.93 beating estimates and revenue up 7.7% year over year to $105.38 billion. The company also raised its quarterly dividend by 15% to $0.94 per share. In September 2026, McKesson's shares hit a 23-week high of $918.80, though later in the month, the stock price hit a 4-week low of $861.47. In October 2026, McKesson shares hit a 4-week high of $924.88. McKesson signed an agreement to acquire Precision Medicine Group, LLC. On October 1, 2026, CVS Health extended its pharmaceutical distribution agreements with Cardinal Health and McKesson, with McKesson's agreement extended through June 2032. On October 6, 2026, McKesson and CD&R signed an agreement to acquire Option Care Health for a total enterprise value of $5.8 billion, with McKesson investing approximately $1.4 billion for a 49% stake.